A Phase 2 interventional study of Reproxalap Ophthalmic Solution (0.25%) and Vehicle Ophthalmic Solution in Dry Eye Syndromes, sponsored by Aldeyra Therapeutics, Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-01-15.
Sponsored by Aldeyra Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing reproxalap in Dry Eye Syndromes — none open to participants now, none under way, none of them phase 3. reproxalap · Dry Eye Syndromes.
Among the 11 studies testing reproxalap in Dry Eye Syndromes, this one is the 9th largest by enrollment, is the only one that started in 2022, is one of 5 in phase 2, and was the 8th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →None of the 11 studies testing reproxalap in Dry Eye Syndromes is open now. The open studies under Dry Eye Syndromes, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 6
First in 2017; this study’s year is marked. 1 started in 2022.
This study's enrollment of 63 is close to the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 158 across the 11 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
Aldeyra Therapeutics, Inc. is the lead sponsor of 35 studies on the registry; 1 is open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 25 (86%) have results posted.
13 studies in Dry Eye Syndromes by Aldeyra Therapeutics, Inc.: none open now, none under way, none of them phase 3. Of 13 finished, 10 (77%) have results posted.
Among the 13 studies in Dry Eye Syndromes by Aldeyra Therapeutics, Inc., this one is the 11th largest by enrollment, is the only one that started in 2022, is one of 6 in phase 2, and was the 10th registered.
Aldeyra Therapeutics, Inc.’s Dry Eye Syndromes studies by the year they started, since 2017.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing reproxalap in Dry Eye Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Aldeyra Therapeutics, Inc.’s 13 in Dry Eye Syndromes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Randomized, Double-Masked, Vehicle-Controlled Crossover Clinical Trial to Assess Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Reproxalap Ophthalmic Solution (0.25%)
Drug: Vehicle Ophthalmic Solution
Reproxalap Ophthalmic Solution (0.25%) dosed six times over two consecutive days
Vehicle Ophthalmic Solution dosed six times over two consecutive days
Conjunctival Redness Assessed Via Digital Photography Over 90 Minutes in the Dry Eye Chamber
Change from baseline comparison of reproxalap to vehicle for conjunctival redness assessed on a 0 to 4 scale (0 = none, 4 = extremely severe). The least squares mean (95% confidence interval) was derived from mixed model repeated measure for change from baseline included baseline as a covariate, and treatment, period, sequence, and time point as factors.
Time frame: The efficacy assessment period was during a 90-minute dry eye chamber; baseline was pre-dose #1 for each treatment period.
Schirmer Test Mean Change From Baseline
Change from baseline comparison of reproxalap to vehicle for schirmer test on a millimeter line (0 = none, 35 = maximum). The least squares mean (95% confidence interval) was derived from mixed model repeated measure for change from baseline included baseline as a covariate, and treatment, period, sequence, and time point as factors.
Time frame: The efficacy assessment period was assessed on the first day of two consecutive dosing days for both crossover periods; baseline was pre-dose #1 for each treatment period.
| Milestone | Reproxalap (0.25%) First, Then Vehicle | Vehicle First, Then Reproxalap (0.25%) |
|---|---|---|
| Started | 32 | 31 |
| Completed | 29 | 28 |
| Not completed | 3 | 3 |
Change from baseline comparison of reproxalap to vehicle for conjunctival redness assessed on a 0 to 4 scale (0 = none, 4 = extremely severe). The least squares mean (95% confidence interval) was derived from mixed model repeated measure for change from baseline included baseline as a covariate, and treatment, period, sequence, and time point as factors.
| score on a scale | Reproxalap (0.25%) | Vehicle |
|---|---|---|
| Conjunctival Redness Assessed Via Digital Photography Over 90 Minutes in the Dry Eye Chamber | 0.33 (0.23 to 0.43) | 0.44 (0.34 to 0.54) |
Change from baseline comparison of reproxalap to vehicle for schirmer test on a millimeter line (0 = none, 35 = maximum). The least squares mean (95% confidence interval) was derived from mixed model repeated measure for change from baseline included baseline as a covariate, and treatment, period, sequence, and time point as factors.
| score on a scale | Reproxalap (0.25%) | Vehicle |
|---|---|---|
| Schirmer Test Mean Change From Baseline | -0.06 (-1.82 to 1.70) | -2.54 (-4.22 to -0.86) |
Collected over Two days for each intervention. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Reproxalap (0.25%) | 0/61 (0%) | 0/61 (0%) | 56/61 (91.8%) |
| Vehicle | 0/60 (0%) | 0/60 (0%) | 2/60 (3.3%) |
| Event | Reproxalap (0.25%) | Vehicle |
|---|---|---|
| General disorders and administration site conditionsGeneral disorders | 56/61 | 2/60 |
| Age, Categorical(Participants) | Reproxalap (0.25%) First, Then Vehicle | Vehicle First, Then Reproxalap (0.25%) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 30 | 29 | 59 |
| >=65 years | 2 | 2 | 4 |
| Age, Continuous(years) | Reproxalap (0.25%) First, Then Vehicle | Vehicle First, Then Reproxalap (0.25%) | Total |
|---|---|---|---|
| Mean | 47.0 ± 13.12 | 51.2 ± 12.14 | 49.1 ± 12.72 |
| Sex: Female, Male(Participants) | Reproxalap (0.25%) First, Then Vehicle | Vehicle First, Then Reproxalap (0.25%) | Total |
|---|---|---|---|
| Female | 17 | 24 | 41 |
| Male | 15 | 7 | 22 |
| Race (NIH/OMB)(Participants) | Reproxalap (0.25%) First, Then Vehicle | Vehicle First, Then Reproxalap (0.25%) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 6 | 6 | 12 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 24 | 19 | 43 |
| More than one race | 0 | 5 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Intraocular Pressure (right eye)(mmHg) | Reproxalap (0.25%) First, Then Vehicle | Vehicle First, Then Reproxalap (0.25%) | Total |
|---|---|---|---|
| Mean | 11.6 ± 2.08 | 12.0 ± 2.76 | 11.8 ± 2.42 |
| Intraocular Pressure (left eye)(mmHg) | Reproxalap (0.25%) First, Then Vehicle | Vehicle First, Then Reproxalap (0.25%) | Total |
|---|---|---|---|
| Mean | 11.7 ± 1.97 | 11.6 ± 2.61 | 11.6 ± 2.29 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2022 to primary completion in May 2022, 2 months.
Results were first posted in Jan 2025, 2 years 8 months after primary completion.
Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 2 months is below that.
Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Reproxalap